- Home
- SCNI vs CNSP Comparison
SCNI vs CNSP Comparison
Compare SCNI & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- CNSP
- Stock Information
- Founded
- SCNI 2003
- CNSP 2017
- Country
- SCNI Israel
- CNSP United States
- Employees
- SCNI N/A
- CNSP N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- CNSP Health Care
- Exchange
- SCNI Nasdaq
- CNSP Nasdaq
- Market Cap
- SCNI 4.6M
- CNSP 4.0M
- IPO Year
- SCNI N/A
- CNSP 2019
- Fundamental
- Price
- SCNI $0.89
- CNSP $6.90
- Analyst Decision
- SCNI
- CNSP Strong Buy
- Analyst Count
- SCNI 0
- CNSP 1
- Target Price
- SCNI N/A
- CNSP $20.00
- AVG Volume (30 Days)
- SCNI 53.1K
- CNSP 15.9K
- Earning Date
- SCNI 11-24-2025
- CNSP 11-17-2025
- Dividend Yield
- SCNI N/A
- CNSP N/A
- EPS Growth
- SCNI N/A
- CNSP N/A
- EPS
- SCNI 0.26
- CNSP N/A
- Revenue
- SCNI $1,147,000.00
- CNSP N/A
- Revenue This Year
- SCNI N/A
- CNSP N/A
- Revenue Next Year
- SCNI N/A
- CNSP N/A
- P/E Ratio
- SCNI $3.30
- CNSP N/A
- Revenue Growth
- SCNI 303.87
- CNSP N/A
- 52 Week Low
- SCNI $0.86
- CNSP $4.93
- 52 Week High
- SCNI $6.18
- CNSP $114.00
- Technical
- Relative Strength Index (RSI)
- SCNI 30.08
- CNSP 46.94
- Support Level
- SCNI $0.86
- CNSP $6.30
- Resistance Level
- SCNI $1.04
- CNSP $6.96
- Average True Range (ATR)
- SCNI 0.08
- CNSP 0.57
- MACD
- SCNI -0.01
- CNSP 0.04
- Stochastic Oscillator
- SCNI 9.07
- CNSP 36.49
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.